Is Pfizer (PFE) Pricing Its Long Term Cash Flow Potential Fairly Today

If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...

Goldman Sachs resets Pfizer stock forecast

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and ...

Should You Forget Pfizer and Buy This Pharma Stock Instead?

Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are two pharmaceutical giants that seem to be headed in opposite directions.

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Pfizer Could Surprise Again This Earnings Season (Preview)

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer (PFE) Valuation Check As COVID Decline And Obesity Pipeline Shift Reshape Its Outlook

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
Hosted on MSN

Pfizer Q1 preview follows cancer trial and patent extension

Pfizer will report first-quarter earnings on May 5, with analysts projecting a notable year-over-year drop in profit but a slight revenue increase. The update comes alongside a positive Phase 3 result ...